Aeglea BioTherapeutics is a holding company. Through its subsidiaries, the company is a biotechnology company developing human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company's development programs include: Pegzilarginase in Arginase 1 Deficiency, which is a recombinant human Arginase 1 that enzymatically degrades the amino acid arginine and improves the stability and arginine-degrading activity of the enzyme in human plasma; and ACN00177 in Homocystinuria, which is a PEGylated, or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine. The company's preclinical pipeline includes AEB5100 Program in Cystinuria.

Amyris is an industrial biotechnology company that applies its technology platform to engineer, manufacture and sell products into the Health and Wellness, Clean Beauty, and Flavor and Fragrance markets. The company's technology platform enables it to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into ingredients. The company is focused on the production of Biofene?, its brand of renewable farnesene, a long-chain, branched hydrocarbon molecule that it manufactures through fermentation using engineered microbes. The company's farnesene derivatives are sold in various products as nutrition, health, skincare, fragrances, solvents, and fragrance ingredients.

Apple Hospitality REIT is a real estate investment trust that invests in real estate, primarily in the lodging sector, in the U.S. The company owns hotels located in urban, suburban and developing markets throughout several states. All of the company's hotels operate under Marriott, Hilton or Hyatt brands. The hotels are operated and managed under separate management agreements with hotel management companies, none of which are affiliated with the company

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer immunotherapies. The company has four clinical-stage product candidates: AB928, which is an orally bioavailable, reversible antagonist of the adenosine 2a and adenosine 2b receptors; AB680, which is a reversible and selective inhibitor of the CD73 enzyme; AB122, which is a human antibody with similar binding affinity and other characteristics to the marketed anti-PD-1 antibodies pembrolizumab and nivolumab; and AB154, which is a humanized antibody that inhibits an immune checkpoint target involved in a pathway that plays both inhibitory and stimulatory roles in the immune system.

Erie Indemnity is an attorney-in-fact for the subscribers (policyholders) at the Erie Insurance Exchange (Exchange), a reciprocal insurer that writes property and casualty insurance. The company's main function as attorney-in-fact is to perform policy issuance and renewal services on behalf of the subscribers at the Exchange. The company also acts as attorney-in-fact on behalf of the Exchange with respect to claims handling and investment management services, as well as the service provider for the claims handling, life insurance, and investment management services for its insurance subsidiaries. The company provides policy issuance and renewal services related to the sales, underwriting and issuance of policies.

Farmland Partners is a real estate company that owns and seeks to acquire farmland located in agricultural markets throughout North America. The company owns farms in Alabama, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana, Michigan, Mississippi, Nebraska, North Carolina, South Carolina, South Dakota, Texas and Virginia. In addition, the main portion of the acres in the company's portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, with the balance used to grow crops, such as blueberries, vegetables, citrus, nuts and edible beans.

High Peak Royalties Ltd. High Peak Royalties Limited is engaged in acquisition of royalty and exploration interests in oil and gas assets predominately in Australia and the United States. The Company has royalties on approximately 23 oil and gas projects, including two royalty areas that are in production, located in Australia and the United States. Its portfolio of royalty interests includes PL 171 and ATP 574P; ATP 299P, including the petroleum leases PL29, PL38, PL39, PL52, PL57, PL95, PL169, PL170, PL293, PL294, PL295 and PL298; Pet Gas Field (PL101); Surprise Oil Field (PL6); Longtom Gas Field (VIC/L29 and VIC/P54); WA-314P; WA-315P; EP115NM; PEL512; WA-482-P; EP156, and East Texas, Permian and Texas Gulf Coast Basins in the United States. Its royalty portfolio has access to projects in main oil and gas basins in Australia. Its portfolio spans producing royalties, potential development royalties and exploration royalties.

Macquarie Infrastructure is a holding company. The company owns and operates a portfolio of businesses that provide services to other businesses, government agencies and individuals primarily in the U.S. The businesses the company owns and operate are: International-Matex Tank Terminals, which provides bulk liquid terminalling services to third parties in the U.S. and in Canada; Atlantic Aviation, which provides fuel, terminal, aircraft hangaring and other services primarily to owners and operators of general aviation jet aircraft at airports throughout the U.S.; and MIC Hawaii, which consist of energy company that processes and distributes gas and provides related services.

Nicholas Financial is a holding company. Through its subsidiary, Nicholas Financial, Inc., the company is engaged primarily in acquiring and servicing automobile finance installment contracts (Contracts) for purchases of used and new automobiles and light trucks. In addition, the company also originates direct consumer loans (Direct Loans) and sells consumer-finance related products. For Automobile Finance Business - Contracts, the company is engaged in the business of providing financing programs, on behalf of purchasers of used cars and light trucks. For Contract Procurement, the Contracts purchased by the company is for used vehicles. For Direct Loans, the loans originated directly between the company and the consumer.

Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The company has product candidates in clinical and preclinical development to treat post-surgical ocular pain and inflammation, allergic conjunctivitis, dry eye disease, among other conditions. The company's drug application, DEXTENZA? (dexamethasone ophthalmic insert) 0.4mg is for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. The company is also assessing the potential use of its hydrogel platform technology in other areas of the body.